PETALING JAYA: The RM1bil cost savings that Malaysia stands to gain by switching to generic drugs could be erased by price hikes of up to 50%, should India’s production costs spike due to geopolitical disruptions.

India is Malaysia’s primary source for generic drugs and relies heavily on the Strait of Hormuz for petroleum-based inputs and energy to run its manufacturing arm, said MBSB Research.